Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Denali Therapeutics Inc. (DNLI) had Return on Tangible Equity of -34.38% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-422.77M |
|
-- |
|
-- |
|
$487.34M |
|
$-487.34M |
|
$64.64M |
|
$-422.70M |
|
$-422.70M |
|
$-422.77M |
|
$-422.77M |
|
$-422.77M |
|
$-422.77M |
|
$-487.34M |
|
$-514.66M |
|
164.47M |
|
164.47M |
|
$-2.57 |
|
$-2.57 |
|
| Balance Sheet Financials | |
$864.44M |
|
$55.24M |
|
$509.74M |
|
$1.37B |
|
$102.21M |
|
$5.62M |
|
$42.29M |
|
$144.50M |
|
$1.23B |
|
$1.23B |
|
$1.23B |
|
144.22M |
|
| Cash Flow Statement Financials | |
$-347.69M |
|
$-88.76M |
|
$484.30M |
|
$128.68M |
|
$176.53M |
|
$47.85M |
|
$102.88M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.46 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-363.61M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-34.38% |
|
|
Return on Tangible Equity |
-34.38% |
-30.77% |
|
-34.22% |
|
$8.53 |
|
$-2.21 |
|
$-2.11 |
|